SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
CEO Christopher Gerteisen met with U.S. Secretary of Energy Chris Wright and other officials in Fairbanks, Alaska, to discuss the company's progress on its Estelle gold and antimon…
The FDA has approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder causing excess red blood cells.
US Digital Mining amended its debt agreement with ChainFi, replacing a prior 8767 loan. The 10-month term accrues interest at 6.5% and requires a balloon principal payment.
AiRWA Inc. received a deficiency notice from Nasdaq for missing the April 30, 2026 deadline to file its annual 10-K report, though the stock is not currently at risk of delisting.
The company dosed nine participants in its ONP-002 trial and received an FDA response regarding its IND application. It also flagged a potential NYSE American delisting due to a $4…
The company received a notice of non-compliance regarding the late filing of its quarterly reports. The oversight prompted a requirement to submit a compliance plan within 48 hours…
Hecla filed Exhibit 23.1, which is an accounting firm's consent for the company's financial statements and form 8-K. This document is typically not a market-moving event.
Flowers Foods has amended its bylaws to state they were effective through August 28, 2026. This ensures the corporate governance framework remains current.
Cytokinetics met primary endpoints in the ACACIA-HCM Phase 3 trial, demonstrating statistically significant improvements in patient-reported outcomes and exercise performance for n…
Aprea Therapeutics added 58 new patents covering its WEE1 and ATR inhibitors to its oncology portfolio. The expansion strengthens the company's intellectual property, protecting it…
Netcapital Inc. was notified it is out of compliance with Nasdaq's filing requirements due to a late 2026 Annual Report on Form 10-K. The company must submit a plan to regain compl…
The US FDA has approved Lisraya (brepocitinib) tablets for treating dermatomyositis in adults, marking the approval of the first oral drug for this indication.
The FDA has issued an Emergency Use Authorization for Ivermectin (Bimectin) injection to prevent New World Screwworm infestations in cattle.
CalciMedica announced a 5-for-1 reverse stock split effective after the filing of an amendment to its certificate of incorporation. This move aims to ensure compliance with Nasdaq'…
The company regained compliance with Nasdaq's minimum bid price requirement, citing a reverse share split. Market impact is neutral as this is a non-discretionary recovery from a p…
Glucotrack will reduce its outstanding shares to approximately 798,144 via a 1-for-15 reverse split, effective at market open on August 31, 2026. This action is necessary to regain…
MBX Biosciences initiated the Phase 3 oPTimize trial for once-weekly canvuparatide in hypoparathyroidism; the initiative positions the biotech firm to vie for a potential best-in-c…
Bermuda legal counsel Conyers Dill & Pearman issued an opinion regarding the issuance and registration of 391,944 common shares to Quaise Energy Inc., related to a Series B Preferr…
U.S. GoldMining has completed over 5,000 meters of drilling at its Whistler gold-copper project and hosted congressional officials, highlighting its potential role in critical mine…
Flash Sports & Media Holdings filed an appeal to a Nasdaq Hearings Panel regarding its listing suspension stemming from an administrative error, and reports a pending reduction of …